Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;2(5):503-512.
doi: 10.1016/j.jacbts.2017.07.012. Epub 2017 Oct 30.

Therapeutic Angiogenesis for Peripheral Artery Disease: Lessons Learned in Translational Science

Sunil R Iyer  1 , Brian H Annex  1   2
Affiliations

Therapeutic Angiogenesis for Peripheral Artery Disease: Lessons Learned in Translational Science

Sunil R Iyer et al. JACC Basic Transl Sci. 2017 Oct.

Abstract

Peripheral arterial disease (PAD) is a major health care problem. There have been limited advances in medical therapies, and a huge burden of symptomatic patients with intermittent claudication and critical limb ischemia who have limited treatment options. Angiogenesis is the growth and proliferation of blood vessels from existing vasculature. For approximately 2 decades, "therapeutic angiogenesis" has been studied as an investigational approach to treat patients with symptomatic PAD. Despite literally hundreds of positive preclinical studies, results from human clinical studies thus far have been disappointing. Here we present an overview of where the field of therapeutic angiogenesis stands today and examine lessons learned from previously conducted clinical trials. The objective is not to second-guess past efforts but to place the lessons in perspective to allow for trial success in the future to improve agent development, trial design, and ultimately, clinical outcomes for new therapeutics for PAD.

Keywords: angiogenesis; critical limb ischemia; gene therapy; peripheral arterial disease.

PubMed Disclaimer

Figures

None
Graphical abstract
Central Illustration
Central Illustration
Potential Patient for Gene Therapy and Routes of Delivery IA = intra-arterial; IM = intramuscular; IV = intravenous.
See this image and copyright information in PMC

References

    1. AnGesMG, Inc. AnGes announces amendment to the global development of HGF plasmid for critical limb ischemia. Available at: http://www.anges-mg.com/en/pdf.php?pdf=100886.pdf. Accessed August 14, 2017.
    1. Isner J., Pieczek A., Schainfeld R. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patient with ischemic limb. Lancet. 1996;348:370–374. - PubMed
    1. Mozaffarian D., Benjamin E.J., Go A.S., on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and Stroke Statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322. - PubMed
    1. Fowkes F.G., Rudan D., Rudan I. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340. - PubMed
    1. Rooke T.W., Hirsch A.T., Misra S. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1555–1570. - PMC - PubMed